These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 28940154)
1. Elsulfavirine: First Global Approval. Al-Salama ZT Drugs; 2017 Oct; 77(16):1811-1816. PubMed ID: 28940154 [TBL] [Abstract][Full Text] [Related]
2. Emerging reverse transcriptase inhibitors for HIV-1 infection. Rai MA; Pannek S; Fichtenbaum CJ Expert Opin Emerg Drugs; 2018 Jun; 23(2):149-157. PubMed ID: 29737220 [TBL] [Abstract][Full Text] [Related]
3. Understanding the reverse transcriptase inhibitors in HIV. Edmonds-Ogbuokiri J Fac Notes (New Orleans La); 1998; 10(6):13-5. PubMed ID: 11366142 [TBL] [Abstract][Full Text] [Related]
4. Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment. Wang Y; De Clercq E; Li G Expert Opin Drug Metab Toxicol; 2019 Oct; 15(10):813-829. PubMed ID: 31556749 [No Abstract] [Full Text] [Related]
5. [Role of etravirine in combination antiretroviral therapy]. Domingo P Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():46-51. PubMed ID: 20116628 [TBL] [Abstract][Full Text] [Related]
6. Identification of a 3-aminoimidazo[1,2-a]pyridine inhibitor of HIV-1 reverse transcriptase. Elleder D; Baiga TJ; Russell RL; Naughton JA; Hughes SH; Noel JP; Young JA Virol J; 2012 Dec; 9():305. PubMed ID: 23231773 [TBL] [Abstract][Full Text] [Related]
7. Doravirine: First Global Approval. Deeks ED Drugs; 2018 Oct; 78(15):1643-1650. PubMed ID: 30341683 [TBL] [Abstract][Full Text] [Related]
8. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies. Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780 [TBL] [Abstract][Full Text] [Related]
9. [Ester derivatives of nucleoside inhibitors of reverse transcriptase: II. Molecular systems for combined therapy with 3'-azido-3'-deoxythymidine and 2',3'-didehydro-3'-deoxythymidine]. Berezovskaia IuV; Chudinov MV Bioorg Khim; 2005; 31(5):451-65. PubMed ID: 16245688 [TBL] [Abstract][Full Text] [Related]
10. Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 update. Zhan P; Liu X; Li Z Curr Med Chem; 2009; 16(22):2876-89. PubMed ID: 19689270 [TBL] [Abstract][Full Text] [Related]
11. An introduction to nucleoside and nucleotide analogues. Squires KE Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469 [TBL] [Abstract][Full Text] [Related]
13. Effect of the substitution of one nucleoside analogue by one non-nucleoside reverse transcriptase inhibitor over mitochondrial DNA levels. De Felipe B; Blanco A; Soriano-Sarabia N; Muñoz-Fernández MA; Genebat M; Vallejo A; Leal M Infection; 2008 Jun; 36(3):266-70. PubMed ID: 18463785 [TBL] [Abstract][Full Text] [Related]
14. [Approval of a new nucleoside. Component of complete once daily regimen]. MMW Fortschr Med; 2004 Apr; 146 Spec No 1():91. PubMed ID: 15373067 [No Abstract] [Full Text] [Related]
15. Rational Design of Doravirine: From Bench to Patients. Hwang C; Lai MT; Hazuda D ACS Infect Dis; 2020 Jan; 6(1):64-73. PubMed ID: 31621289 [TBL] [Abstract][Full Text] [Related]
17. [Discovery and development of diarylpyrimidines (DAPYs) as next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs)]. Tian XT; Xie L Yao Xue Xue Bao; 2010 Feb; 45(2):177-83. PubMed ID: 21351427 [TBL] [Abstract][Full Text] [Related]
18. Stampidine as a novel nucleoside reverse transcriptase inhibit with potent anti-HIV activity. Uckun FM Arzneimittelforschung; 2006 Feb; 56(2A):121-35. PubMed ID: 16570821 [TBL] [Abstract][Full Text] [Related]
19. [Resistance profile of rilpivirine]. Imaz A; García F; di Yacovo S; Llibre JM Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():36-43. PubMed ID: 24252532 [TBL] [Abstract][Full Text] [Related]
20. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens. Joly V; Descamps D; Yeni P AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]